Agomelatine-induced liver injury in a patient with choledocholithiasis.

IF 2.6 4区医学 Q3 NEUROSCIENCES

Acta Neuropsychiatrica Pub Date : 2015-02-01 Epub Date: 2014-10-22 DOI:10.1017/neu.2014.28

Piotr Eder, Agnieszka Permoda-Osip, Przemyslaw Majewski, Krzysztof Linke, Janusz K Rybakowski

{"title":"Agomelatine-induced liver injury in a patient with choledocholithiasis.","authors":"Piotr Eder, Agnieszka Permoda-Osip, Przemyslaw Majewski, Krzysztof Linke, Janusz K Rybakowski","doi":"10.1017/neu.2014.28","DOIUrl":null,"url":null,"abstract":"Objective: A case of agomelatine-induced hepatotoxicity is described in a 47-year female patient who has received the drug, 25 mg/day, for 4 months, for the treatment of depression.Methods: The patient was admitted to the Department of Gastroenterology because of fatigue and nausea, with concomitant elevation of alanine aminotransferase (ALT), 550 U/L, and asparagine aminotransferase (AST), 300 U/L.Results: Liver biopsy showed diffuse lymphocyte infiltration in the dilated portal spaces without lesion of hepatic lobules. Several weeks after stopping agomelatine, the liver enzymes returned to normal. Subsequently, small gallstones in common bile duct were detected and removed by the endoscopic sphincterotomy.Conclusions: It is hypothesized that choledocholithiasis could theoretically increase a risk of developing agomelatine-induced hepatotoxicity in this patient. Any pre-existing liver disease should be a contraindication for treatment with agomelatine.","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/neu.2014.28","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropsychiatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/neu.2014.28","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/10/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 3

Abstract

Objective: A case of agomelatine-induced hepatotoxicity is described in a 47-year female patient who has received the drug, 25 mg/day, for 4 months, for the treatment of depression.

Methods: The patient was admitted to the Department of Gastroenterology because of fatigue and nausea, with concomitant elevation of alanine aminotransferase (ALT), 550 U/L, and asparagine aminotransferase (AST), 300 U/L.

Results: Liver biopsy showed diffuse lymphocyte infiltration in the dilated portal spaces without lesion of hepatic lobules. Several weeks after stopping agomelatine, the liver enzymes returned to normal. Subsequently, small gallstones in common bile duct were detected and removed by the endoscopic sphincterotomy.

Conclusions: It is hypothesized that choledocholithiasis could theoretically increase a risk of developing agomelatine-induced hepatotoxicity in this patient. Any pre-existing liver disease should be a contraindication for treatment with agomelatine.

查看原文本刊更多论文

阿戈美拉汀致胆总管结石患者肝损伤1例。

目的:报告一例47岁女性阿戈美拉汀所致肝毒性病例，该药25毫克/天，治疗抑郁症4个月。方法:患者因疲劳、恶心，同时伴有谷丙转氨酶(ALT)升高550 U/L，天冬酰胺转氨酶(AST)升高300 U/L，入住消化内科。结果:肝活检示肝门静脉间隙弥漫性淋巴细胞浸润，肝小叶未见损伤。停用阿戈美拉汀几周后，肝酶恢复正常。随后，经内镜下括约肌切开术在胆总管内发现小结石并取出。结论:假设胆总管结石理论上可能增加该患者发生阿戈美拉汀引起的肝毒性的风险。任何先前存在的肝脏疾病都是阿戈美拉汀治疗的禁忌症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Neuropsychiatrica NEUROSCIENCES-PSYCHIATRY

自引率

5.30%

发文量

期刊介绍： Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal''s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health.